Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update …
S Johnson, V Lavergne, AM Skinner… - Clinical infectious …, 2021 - academic.oup.com
This clinical practice guideline is a focused update on management of Clostridioides difficile
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …
Synthetic glycans to improve current glycoconjugate vaccines and fight antimicrobial resistance
L Del Bino, KE Østerlid, DY Wu, F Nonne… - Chemical …, 2022 - ACS Publications
Antimicrobial resistance (AMR) is emerging as the next potential pandemic. Different
microorganisms, including the bacteria Acinetobacter baumannii, Clostridioides difficile …
microorganisms, including the bacteria Acinetobacter baumannii, Clostridioides difficile …
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
P Feuerstadt, TJ Louie, B Lashner… - … England Journal of …, 2022 - Mass Medical Soc
Background Current therapies for recurrent Clostridioides difficile infection do not address
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …
Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021
Background & Aims Gastrointestinal diseases account for considerable health care use and
expenditures. We estimated the annual burden, costs, and research funding associated with …
expenditures. We estimated the annual burden, costs, and research funding associated with …
Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of …
Abstract Background Recurrent Clostridioides difficile infection, associated with dysbiosis of
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …
Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics
Clostridioides difficile is a Gram-positive anaerobe that can cause a spectrum of disorders
that range in severity from mild diarrhoea to fulminant colitis and/or death. The bacterium …
that range in severity from mild diarrhoea to fulminant colitis and/or death. The bacterium …
VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial
Importance The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains
of Clostridia on prevention ofClostridioides difficileinfection (CDI) is unknown. Objective To …
of Clostridia on prevention ofClostridioides difficileinfection (CDI) is unknown. Objective To …
Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit
Despite enhanced infection prevention efforts, Clostridioides difficile remains the leading
cause of healthcare-associated infections in the United States. Current prevention strategies …
cause of healthcare-associated infections in the United States. Current prevention strategies …
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial
SMD Baunwall, SE Andreasen, MM Hansen… - The Lancet …, 2022 - thelancet.com
Background Clostridioides difficile infection is an urgent antibiotic-associated health threat
with few treatment options. Microbiota restoration with faecal microbiota transplantation is an …
with few treatment options. Microbiota restoration with faecal microbiota transplantation is an …
ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections
Clostridioides difficile infection occurs when the bacterium produces toxin that causes
diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to …
diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to …